期刊文献+

难治性抑郁症的治疗进展 被引量:51

Research progress of the therapy in treatment-resistant depression
原文传递
导出
摘要 难治性抑郁症是一种常见的、严重的精神疾病,与重大疾病负担相关。大多数患者接受传统抗抑郁药物治疗后不能获得症状缓解,因此对临床医生而言仍是精神医学面临的难题之一。通过归纳总结近年来国内外关于难治性抑郁症治疗的研究,提示目前该病的疗效仍不容乐观,但其治疗取得很大进展。目前常用的治疗方法有新型快速抗抑郁药、具有抗抑郁作用的其他药物、心理治疗、电休克治疗、经颅磁刺激、磁共振引导下聚焦超声术、深部脑刺激、有氧运动、光照疗法等,每种治疗策略均有其优缺点和特殊的研究价值。一线治疗策略的高度未缓解率使得安全性较高的新型抗抑郁药、具有抗抑郁作用的其他药物与非药物治疗手段相结合成为治疗难治性抑郁症未来发展的方向。 Treatment resistant depression is a common and severe mental disorder associated with significant burden of disease .Most individuals receiving conventional pharmacotheraphy fail to achieve and sustain remission.So this is still one of the difficult challenges for the psychiatrist .Much of the research pro-vided indications that the efficacy of treatment for the disease was not optimistic, but the treatment was still made great progress .The common treatments for this disease included pharmacotherapy,psychotherapy,elec-troconvulsive therapy(ECT),transcranial magnetic stimulation (TMS),magnetic resonance guided focused ultrasound surgery( MRgFUS) ,deep brain stimulation ( DBS) ,aerobic exercise,light therapy and so on.Each therapeutic strategy has its own features, and could be suitable or unsuitable in some situations.The high rates of non-remission with first-line treatment strategies make the combination of antidepressant and non-drug treatments to be the new trend of the treatments for treatment resistant depression in the future.
出处 《中华行为医学与脑科学杂志》 CAS CSCD 北大核心 2016年第3期280-284,共5页 Chinese Journal of Behavioral Medicine and Brain Science
关键词 难治性抑郁症 药物治疗 非药物治疗 Treatment-resistant depression Pharmacotherapy Non-drug treatment
  • 相关文献

参考文献31

  • 1王彦芳,杜巧荣,赵晋霞,叶峰华,武克文,母跃生,刘伟,张克让.难治性抑郁症患者认知功能损害特点及临床治疗效果[J].中华行为医学与脑科学杂志,2014,23(7):594-597. 被引量:28
  • 2O'Leary OF, Dinah TG, Cryan JF. Faster, better, stronger : towards new antidepressant therapeutic strategies [ J ]. Eur J Pharmacol, 2015,753:32-50. DOI: 10. lO16/j.ejphar.2014.07.046.
  • 3徐华,叶冬青,李晓莉,张志珺.TREK-1钾通道介导的抗抑郁及神经保护作用[J].中华行为医学与脑科学杂志,2015,24(12):1144-1146. 被引量:2
  • 4Montgomery SA, Nielsen RZ, Poulsen LH, et al. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin re- uptake inhibitor or serotonin-noradrenaline reuptake inhibitor treat- ment switched to vortioxetine or agomelatine [ J ]. Hum Psychophar-maeo1,2014,29 ( 5 ) :470-482. DOI : 10.1002/hup.2424.
  • 5Blum SI, Tourkodimitris S, Ruth A. Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder [ J ]. J Affect Disord, 2015, 170:230-236. DOt : 10.1016/j.jad.2014.09.005.
  • 6Asnis GM, Henderson MA. Levomilnacipran for the treatment of major depressive disorder: a review [ J ]. Neuropsyehiatr Dis Treat, 2015,11 : 125-135. DOI : 10.2147/NDT.S54710.
  • 7Learned S, Craft O, Roychowdhury S, et al. Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treat- ment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials[J]. J Psychopharma- col, 2012,26 ( 5 ) : 653 -662. DOI : 10.1177/0269881111424931.
  • 8Wang Y, Chang T, Chen YC, et al. Quetiapine add-on therapy im- proves the depressive behaviors and hippocampal neurogenesis in fluoxetine treatment resistant depressive rats[ J]. Behav Brain Res, 2013,253:206-211. DOI : 10.1016/j.bbr.2013.07.021.
  • 9Lenze EJ, Mulsant BH, Blumberger DM, et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life : a randomised, double- blind, placebo-controlled trial [ J ]. Lancet, 2015, 386 ( 10011 ) : 2404-2412. DOI : 10.1016/S0140-6736 ( 15 ) 00308-6.
  • 10Tamayo JM, Pica-Ruiz Y, Ruiz I. Olanzapine and fluoxetine com- bined as therapy for treatment-resistant depression: a systematic review[ J]. Arch Neurocien ,2015,20( 1 ) : 17-33.

二级参考文献75

  • 1陈双庆,蔡庆,沈玉英,赵中,周华.轻度认知功能损害患者扣带后回谷氨酸多体素氢质子磁共振波谱研究[J].中华诊断学电子杂志,2013,1(1). 被引量:33
  • 2Wiles N, Thomas L, Abel A, et al. Clinical effectiveness and cost-ef- fectiveness of cognitive behavioural therapy as an adjunct to pharmaco- therapy for treatment-resistant depression in primary care:the CoBalT randomised controlled trial [ J ]. Health Technol Assess, 2014, 18 (31) :1-167.
  • 3Fitas A, Berent D, Talarowska M. Differences in cognitive functioning of men and women with a diagnosis of depression [ J l.Pol Merkur Lek- arski ,2010,28(165) : 199-202.
  • 4vottel BJ, Potter GG, WiUiams HT, et al.The moderating role of per- sonality factors in the relationship between depression and neuropsy- chological functioning among older adults [ J ].Int J Geriatr Psychiatry,2009,24(9):1010-1019.
  • 5Potvin O, Bergua V, Meillon C, et al.State anxiety and cognitive func- tioning in older adults [J].Am J Geriatr Psychiatry, 2013,21 (9) :915- 924.
  • 6Monzon S, Gili M,Vives M, et al.Melancholic versus non-melancholic depression : differences on cognitive function [ J ]. A longitudinal study protocol.BMC Psychiatry, 2010,10:48.
  • 7Niciu M J, Luckenbaugh DA,Ionescu DF, et al. Clinical predictors of ketamine response in treatment-resistant major depression [ J ]. J Clin Psychiatry, 2014,75 ( 5 ) :e417-423.
  • 8Story TJ, Potter GG, Attix DK, et al. Neuroeognitive correlates of re- sponse to treatment in late-life depression [ J ]. Am J Geriatr Psychia- try,2008,16(9) :752-759.
  • 9Rabinowitz AR, Arnett PA. A longitudinal analysis of cognitive dys- function, coping, and depression in multiple sclerosis [ J ]. Neuropsy- chology, 2009,23 ( 5 ) : 581-591.
  • 10Stryjer R, Budnik D, Ebert T, et al. Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs-an open-label study[ J]. Clin Neuropharmacol,2014,37(3) :79-81.

共引文献29

同被引文献460

引证文献51

二级引证文献431

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部